Overview

Investing.com’s AI‑driven Bharat Mid‑Cap Movers strategy, which targets high‑growth Indian mid‑cap firms, launched on 25 December 2024 and has delivered a cumulative return of +14.29% to date, outperforming the NIFTY Midcap 100 by 13.54 percentage points. For the calendar year 2026 the strategy is up +4.82%, a gap of 9.61 points over the benchmark, and in November 2026 it is up +1.58% versus the index’s +0.87%.

Top Performers Carrying Into November

  • Alivus Life Sciences (NSE: ALIVUS) entered the list on 1 July at ₹1,132.36 and has generated a +28.0% return.
  • Marksans Pharma (NSE: MARKSANS) entered on 1 July at ₹268.11, up +16.2%.
  • Akums Drugs & Pharmaceuticals (NSE: AKUMS) entered on 1 August at ₹658.35, up +10.9%.
  • Rain Industries (BSE: 500339) entered on 1 July at ₹182.19, up +9.1%.
  • Nazara Technologies (NSE: NAZARA) entered on 1 October at ₹384.70, up +4.6%.
  • IIFL Capital (NSE: IIFLCAPS) entered on 1 August at ₹337.80, up +3.0%.
  • Powergrid Infrastructure InvIT (NSE: PGINVIT) entered on 1 October at ₹101.84, up +3.1%.

Alivus Life Sciences Q2 FY27 Results

Alivus reported Q2 FY27 on 30 October: revenue from operations ₹682 crore, a 16.0% YoY increase; EBITDA ₹285.1 crore, up 47.0% YoY, delivering an EBITDA margin of 41.8% (an 880‑bp expansion). Net profit was ₹196.8 crore, up 51.3% YoY, giving a PAT margin of 28.9% (680‑bp rise). Free cash flow amounted to ₹270.2 crore and the balance sheet held ₹1,011.6 crore in cash and short‑term investments. CEO Yasir Rawjee credited the revenue growth to healthy demand and recent product launches, and indicated that the company will focus on Solapur Phase 1 in Q3 FY27 and Phase 2 in Q4 FY27.

November Rebalance – New Additions

The November 1 reset added three stocks, each at an equal‑weight of 5% (the strategy caps at 20 names): Bombay Burmah Trading (BSE: 501425), Tata Chemicals (BSE: 500770) and Firstsource Solutions (NSE: FSL). These securities have no performance record within the strategy yet.

Methodology Snapshot

Investing.com’s proprietary AI evaluates thousands of global equities each month using over 15 years of financial data and more than 150 quantitative models. Up to 20 high‑conviction stocks are selected per strategy, rebalanced monthly, and held with equal weighting to limit concentration risk. Investors may adjust allocations, but the equal‑weight framework provides a transparent benchmark.

Data as of 2 November 2026.